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Abstract
Osteocalcin (OC) is an osteoblast-derived vitamin K dependent protein. Recent studies have demonstrated that in mice it acts as 
a multifunctional hormone, increasing insulin secretion and beta cell proliferation and improving insulin sensitivity. Osteocalcin 
has been postulated to be metabolically active in its undercarboxylated form. Whether OC plays a similar metabolic role in the 
rat is currently unknown. The aim of the present study was to compare the levels of OC in intact rats and in rats with a diet-
induced metabolic syndrome. A secondary objective was to look for correlations of OC with metabolic parameters. Two groups 
of rats were used. The control group received regular rat chow and plain water and the experimental group was fed a diet high 
in saturated fat and fructose. The duration of the experiment was 10 weeks. At the end of this period insulin tolerance test was 
performed. Serum lipids, insulin, leptin and both forms of OC, carboxylated and undercarboxylated, were determined. Meta-
bolic syndrome was veri!ed by increased visceral adiposity, elevated serum triglycerides, cholesterol and fasting blood glucose, 
positive insulin tolerance test at the 90th minute, higher serum insulin. In rats with metabolic syndrome  undercarboxylated OC 
serum level was signi!cantly reduced, whereas carboxylated OC level was unchanged. The ratio undercarboxylated OC/ carbox-
ylated OC was also lower in the experimental group. Undercarboxylated OC and undercarboxylated OC/ carboxylated OC were 
inversely associated with blood glucose but not with other biochemical parameters. Our results partly support the hypothesis 
that undercarboxylated OC is implicated in energy regulation and suggest that this might be true also for the rat. More evidence 
is needed to determine the hormonal role of osteocalcin in this animal species. 
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Introduction
Osteocalcin (OC) is a protein typical for bones. It was isolated in 
1975 by two independent research groups (1, 2). It is produced by 
osteoblasts, incorporated in bone matrix and released in circula-
tion through the process of bone resorption. Traditionally OC is 
regarded as a marker of bone formation (3). It is also known as 
bone Gla-protein since its molecule contains three gamma-glu-
tamic acid residues that undergo vitamin K dependent gamma-
glutamic carboxylation. In this way, the undercarboxylated OC is 
converted to its carboxylated form. In general, OC is considered, 
like the other vitamin K dependent proteins (e.g. those involved in 
coagulation), as active in its carboxylated form, vitamin K being 
essential for its functional activity in the bone.  
!e classical understanding about the role of OC in skele-
ton was shaken when a research group led by Gerard Karsen-
ty at Columbia University, New York, NY, USA demonstrated 
in experiments on OC knock-out mice that they had virtually 
normal bones. Unexpectedly, however, these mice consistently 
developed obesity phenotype with glucose intolerance and insu-
lin resistance. It turned out from these and later studies that, at 
least in mice, OC exerted metabolic functions (4). !us, OC has 
been quali"ed as a hormone (osteokine) secreted by bone and 
involved in the regulation of energy homeostasis through ac-
tions on pancreatic beta cells and adipocytes. According to this 
hypothesis, OC is decarboxylated during bone resorption and 
released into the systemic circulation in its undercarboxylated 
form. !erefore, it is the undercarboxylated OC that exerts a 
hormonal action. !e release of undercarboxylated OC into the 
blood is under the positive control of insulin (5) and is negative-
ly regulated by leptin (6). Metabolic e#ects of undercarboxylated 
OC include increased insulin secretion and pancreatic beta cell 
proliferation and enhanced insulin sensitivity in adipose tissue 
and skeletal muscles (4, 7). Treatment of mice subjected to high-
fat diet with undercarboxylated OC improves insulin sensitivity 
and glucose tolerance, reduces plasma triglycerides and protects 
the animals from diet-induced obesity and hepatic steatosis (7, 8). 
!e intriguing new "ndings suggesting a role for OC in 
obesity, metabolic syndrome  and type 2 diabetes mellitus was 
re$ected by a number of clinical and epidemiological studies 
undertaken to test this hypothesis in humans. Early clinical 
observations considered total OC and found associations with 
parameters of glucose and lipid metabolism in individuals with 
type 2 diabetes (9-11) or metabolic syndrome  (12-15). !e 
relationships between undercarboxylated OC and energy ho-
meostasis have been less investigated so far and the results are 
controversial. Some studies support the hypothesis that under-
carboxylated OC is the active metabolic form of OC (16-20). 
Others demonstrate metabolic activity of carboxylated OC as 
well (19, 21). Still others "nd no relationship between undercar-
boxylated OC and carbohydrate homeostasis (21, 22). !e het-
erogeneity of results in humans poses the question about pos-
sible variability of OC actions in di#erent animal species.
Whether OC serves a metabolic role in the rat is currently 
unknown. !e aim of the present study was to compare the lev-
els of OC in intact rats and in rats with diet-induced metabolic 
syndrome and to look for correlations of both forms of OC with 
biochemical measures of glucose and lipid homeostasis.
Materials and Methods
Experimental animals
!e study was performed on 20 male Wistar rats. !e ani-
mals were kept at an ambient temperature of 20-25 °C and 12-
hour light-dark cycle. !ey had free access to food and water. 
!e study was approved by the Commission of foods safety in 
the Ministry of Agriculture and Foods and was conducted in 
agreement with the National Policies and the Council Directive 
(86/609/EEC).
!e rats were allocated into two groups of 10 rats each, with 
initial average body weight of 258 g in both groups. !e duration 
of the study was 10 weeks. !e "rst group was a control group 
(C) and the second group was an experimental group with diet-
induced metabolic syndrome.
Diets 
!e rats from the C group were fed a standard rat chow and were 
given plain water to drink. With each 100 g food consumed, 
these animals received 279 kcal. !e second group of  rats was 
subjected to a diet-induced model of metabolic syndrome (23). 
!ey were given a diet with lard (17%) and fructose (17%) added 
to the standard rat chow and a 10% fructose solution to drink in-
stead of water. !e caloric intake was 405 kcal per 100 g food of 
which 38% was provided by lard and 17% by fructose. !ese ani-
mals received also additional 40 kcal per 100 ml of the fructose 
solution consumed. Body weight of the animals was measured 
every other day. At the end of the experiment insulin tolerance 
test and biochemical tests were performed. 
Insulin tolerance test 
Insulin tolerance test (ITT) was carried out a'er 4 hours of fast-
ing. Regular insulin (ActRapid), dissolved in saline, was used at 
a dose 0.75 UI/kg. Animals were injected i.p. with 0.2 ml/100 g 
body weight insulin solution. Blood glucose was measured by 
a glucometer (ACCU-CHEK Performa). Blood samples were 
taken by incision of the distal part of the tail (24) immediately 
before the injection of insulin (at time 0) and at the 30th, 60th 
and 90th minute. !e blood glucose levels at time 0 will be con-
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sidered as fasting blood glucose in the further text. Blood for 
biochemical tests was taken from the sublingual veins of the ani-
mals under ether anesthesia. e blood was centrifuged and the 
serum was refrigerated at -20˚C until biochemically tested. e 
rats were euthanized by cervical dislocation. e abdomen was 
opened and the right retroperitoneal fat pad was dissected out, 
weighed and the fat index was calculated as a ratio of fat weight 
to body weight x 103.
Biochemical tests
Serum triglycerides and cholesterol were measured by using 
colorimetric kits of HUMAN, LINEAR CHEMICALS S.L., Bar-
celona, SPAIN, at a spectrophotometer AURIUS 2021 (Cecil 
Instruments Ltd.). Serum insulin and leptin, as well as serum 
levels of both forms of OC – undercarboxylated and carboxyl-
ated, were measured by ELISA assay kits (Rat Insulin ELISA Kit 
of Shibayagi, Rat Leptin ELISA Kit of BioVendor, Rat Glu-Os-
teocalcin and Rat Gla-Osteocalcin ELISA Kits of Takara), fol-
lowing the producer’s instructions. e ratio undercarboxylated 
OC/ carboxylated OC was calculated.
Statistics 
Results are presented as a mean ± standard error of the mean 
(SEM). e two groups were compared by Student’s unpaired t-
test. Associations between OC levels and metabolic parameters 
were analyzed by correlation analysis. Di"erences were consid-
ered signi#cant at p<0.05. e statistical so$ware GraphPad 
Prism 5 was used (GraphPad So$ware, Inc.).
Results
A$er 10 weeks of diet manipulation the body weight of the ani-
mals from the experimental group did not di"er signi#cantly 
from that of controls. e metabolic syndrome induced by the 
diet was veri#ed by increased visceral adipose tissue (fat index), 
Table 1. Veri!cation of metabolic syndrome – metabolic char-
acteristics of animals from the control and the metabolic syn-





Final body weight (grams) 374.4 ± 8.2 353.0 ± 8.6
Fat index 7.94 ± 0.77 11.71 ± 1.25*
Triglycerides (mmol/l) 1.626 ± 0.07 1.967 ± 0.13*
Cholesterol (mmol/l) 2.469 ± 0.04 2.631 ± 0.06*
Fasting blood glucose (mmol/l) 5.97 ± 0.11 6.48 ± 0.14*
ITT at the 90th minute (% of initial value) 38.1 ± 1.75 44.3 ± 1.87*
Fasting insulin (ng/ml) 0.79 ± 0.11 1.53 ± 0.24*
Leptin (pg/ml) 16.5 ± 4.86 49.8 ± 18.16
Figure 1. Changes in osteocalcin (OC) levels in rats with metabolic syndrome (MS) compared to control rats (C); A. Changes in 
serum level of undercarboxylated osteocalcin (ucOC). B. Changes in serum level of carboxylated osteocalcin (cOC). C. Changes 















































elevated serum triglycerides, cholesterol and fasting blood glu-
cose, positive ITT at the 90th minute, higher insulin and leptin 
levels (Table 1). Changes in OC levels are shown on Figure 1. In 
the rats with metabolic syndrome, the level of undercarboxyl-
ated OC (Fig. 1A) was decreased: 27.12  ± 2.287 ng/ml in the 
MS group compared to 40.31 ± 4.674 ng/ml in the C group 
(t=2.535, df=16, p=0.0221). e carboxylated OC level (Fig. 1B) 
was insigni#cantly increased: 577.2 ± 49.96 ng/ml in the meta-
bolic syndrome  group compared to 486.1±39 ng/ml in the C 
group (t=1.436, df=16, p=0.1702). e ratio undercarboxylated 
OC/ carboxylated OC (Fig. 1C) was also reduced in the experi-
mental group: 0.03957 ± 0.0037 in the MS group compared to 
0.08163 ± 0.0034 in the C group (t=8.341, df=13, p<0.0001). 
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Correlation analysis (Fig.2) revealed that the level of undercar-
boxylated OC was negatively associated with fasting blood glu-
cose (Fig. 2A): Pearson r=-0.5409, p=0.0250. !e same was true 
for the ratio undercarboxylated OC/ carboxylated OC (Fig. 2B): 
Pearson r=-0.6644, p=0.0096. 
No associations were found between undercarboxylated OC 
and visceral adipose tissue, serum insulin, leptin, triglycerides 
and cholesterol levels. Carboxylated OC showed no correlations 
with any of the metabolic parameters examined.
Discussion
!e results from the present study demonstrate that OC is most 
probably involved in the regulation of energy homeostasis in 
rats, similarly to its actions in mice. Obviously, it is the under-
carboxylated form of the protein that is likely endowed with 
hormonal activity. 
!e diet high in saturated fat and fructose induced in the ex-
perimental rats a state similar to metabolic syndrome  in hu-
mans, evidenced by somatic and biochemical measures. Insulin 
resistance was presented by increased fasting level of serum in-
sulin and impaired response to insulin at the 90th minute of the 
ITT. !e reduced insulin sensitivity a"ects not only the adipose 
tissue, liver and skeletal muscles, but also the insulin receptors 
on osteoblasts. In mice  increased uptake of saturated fatty ac-
ids by osteoblasts accelerates the ubiquitination and degradation 
of insulin receptors (25). Insulin signaling in osteoblasts is re-
sponsible for the regulation of OC secretion in the circulation 
(5). Activation of insulin receptors suppresses the production 
of osteoprotegerin, an inhibitor of osteoclast maturation. !e 
bone resorption is thus stimulated, providing the acidic envi-
ronment needed for the decarboxylation and the activation of 
OC. Insulin resistance, as seen in MS, impairs this regulatory 
mechanism and results in reduced circulating level of undercar-
boxylated OC. !is is what we observed also in our experiment 
in rats: the concentration of undercarboxylated OC was reduced 
in the rats fed energy-dense diet compared to controls. Unlike 
undercarboxylated OC, carboxylated OC level was not a"ected 
by the diet manipulation. It was only slightly and insigni#cantly 
elevated. !ese results suggest that carboxylated OC is not in-
volved in the regulation of energy homeostasis, whereas under-
carboxylated OC exerts hormonal activity in rats. It appears that 
the ratio between the undercarboxylated and carboxylated OC 
even better re$ects the diet-induced metabolic alterations in the 
rats in our experimental setting.
Increased leptin levels may also contribute to the decrease of 
serum undercarboxylated OC level since leptin is another endo-
crine factor involved in the regulation of its release (6). By stim-
ulating the sympathetic tone, leptin leads to activation of β2-
adrenergic receptors on osteoblasts, #nally resulting in reduced 
release of undercarboxylated OC. In our experiment, however, 
leptin was probably not implicated in the decrease of undercar-
boxylated OC, since its increase was not statistically signi#cant. 
On the other hand, higher leptin level can be regarded as a fea-
ture of the metabolic syndrome  itself with development of resis-
tance, where the e"ect of leptin on undercarboxylated OC might 
be blunted.
All the cited experimental studies concerning the hormonal 
role of undercarboxylated OC have been carried out on mice – 
genetically modi#ed in di"erent ways and wild type mice.
Our results are the #rst to show that in the rat OC may have 
a metabolic role too. In addition to the decreased level of under-
carboxylated OC and the lower ratio between undercarboxyl-
ated and carboxylated OC in the MS rats, this notion is further 
reinforced by the inverse correlations that we found between 
Figure 2. Correlations of: A. Undercarboxylated OC (ucOC) with fasting blood glucose and B. Undercarboxylated to carboxyl-
ated OC ratio (ucOC/cOC) with fasting blood glucose.
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these variables and the fasting blood glucose. Ferron et al (8) 
have shown that in mice undercarboxylated OC is involved in 
the pathogenesis of metabolic disorders. !ey demonstrated 
that mice fed high-fat diet can be protected from type 2 diabetes 
by daily injections of undercarboxylated OC. Under the condi-
tions of diet manipulation, undercarboxylated OC is probably 
involved in a vicious cycle – insulin resistance leads to decreased 
release of undercarboxylated OC and the reduced undercarbox-
ylated OC level results in further impairment of insulin sensi-
tivity. !e negative association between undercarboxylated OC 
and the fasting blood glucose that we have observed seems a 
logical consequence of the metabolic derangement following 
diet loading. Furthermore, carboxylated OC correlated neither 
with blood glucose nor with any other metabolic or somatic 
parameter. However, we did not "nd any correlation of under-
carboxylated OC with biochemical measures other than blood 
glucose. We could speculate that undercarboxylated OC in rats 
is less metabolically active than in mice. 
While our results partly replicated those in mice, they appear 
to be closer to those results observed in humans that are in line 
with the murine. In general, the data from the clinical observa-
tions are very inconsistent. In earlier studies the total OC has 
been investigated and negative associations with blood glucose 
have been reported in patients with type 2 diabetes or meta-
bolic syndrome  (9-15). In these studies OC was also positively 
or negatively correlated with a variety of other variables, such 
as insulin and/or adiponectin levels, insulin resistance and/or 
sensitivity measures, serum triglycerides and HDL-cholesterol, 
body mass index, waist circumference and blood pressure. 
!e undercarboxylated form of OC in healthy individuals or 
in type 2 diabetic patients has been found to be negatively as-
sociated with blood glucose (16, 19, 20), similarly to what we 
have observed in rats. In other studies undercarboxylated OC 
was positively correlated with insulin sensitivity (17), adiponec-
tin levels (18) and pancreatic beta cell function (19). 
Some epidemiological studies suggest that in humans both 
forms of OC are involved in regulation of energy homeostasis. 
According to Hwang et al undercarboxylated OC was associ-
ated with enhanced beta cell function, while carboxylated OC 
correlated with improved insulin sensitivity (19). Other authors 
found that low levels of carboxylated, but not undercarboxylated 
OC, were associated with insulin resistance (21). Further on, it 
has been reported that the decrease of undercarboxylated OC in 
response to vitamin K supplementation had no e#ect on insulin 
resistance suggesting that this form of OC is not involved in the 
regulation of glucose metabolism in humans (22). 
Our results in rats are discordant with the reported endocrine 
activity for carboxylated OC in humans and with the lack of e#ect 
of its undercarboxylated form, rather, they support the hormonal 
function of the undercarboxylated OC on the energy homeosta-
sis.We may thus propose that, despite the "rm evidence about the 
hormonal role of undercarboxylated OC in mice, in humans the 
results are not so homogeneous in their agreement as to whether 
and which form of OC is hormonally active in regulating energy 
homeostasis. Combined with our modest results on rats, the data 
thus far seem to point to the possibility that OC might not behave 
in the same manner in di#erent animal species.
Conclusion
!e present study provides some support to the hypothesis 
that OC is implicated in energy regulation in the rat. Similarly 
to mice, the undercarboxylated OC was the form that was im-
plicated in the metabolic changes in the diet-manipulated rats. 
However, compared to its e#ects in mice, the metabolic activity 
of undercarboxylated OC in rats might turn out to be more limit-
ed. Given the contradictory results that have been reported from 
human studies looking at the role of OC in regulation of energy 
homeostasis, it can be inferred that species di#erences prob-
ably exist in its hormonal activity. De"nitely much more work 
is needed to convincingly determine whether OC is involved in 
metabolic regulation in the animal kingdom as a whole. 
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